Nkuba A. N., Makiala S. M., Guichet Emilande, Tshiminyi P. M., Bazitama Y. M., Yambayamba M. K., Kazenza B. M., Kabeya T. M., Matungulu E. B., Baketana L. K., Mitongo N. M., Thaurignac G., Leendertz F. H., Vanlerberghe V., Pelloquin Raphael, Etard Jean-François, Maman D., Mbala P. K., Ayouba Ahidjo, Peeters Martine, Muyembe J. J. T., Delaporte E., Ahuka S. M. (2022). High prevalence of anti-severe acute respiratory syndrome coronavirus 2 (anti-sars-cov-2) antibodies after the first wave of coronavirus disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo : results of a cross-sectional household-based survey. Clinical Infectious Diseases, [Early access], [9 p.]. ISSN 1058-4838.
Titre du document
High prevalence of anti-severe acute respiratory syndrome coronavirus 2 (anti-sars-cov-2) antibodies after the first wave of coronavirus disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo : results of a cross-sectional household-based survey
Année de publication
2022
Auteurs
Nkuba A. N., Makiala S. M., Guichet Emilande, Tshiminyi P. M., Bazitama Y. M., Yambayamba M. K., Kazenza B. M., Kabeya T. M., Matungulu E. B., Baketana L. K., Mitongo N. M., Thaurignac G., Leendertz F. H., Vanlerberghe V., Pelloquin Raphael, Etard Jean-François, Maman D., Mbala P. K., Ayouba Ahidjo, Peeters Martine, Muyembe J. J. T., Delaporte E., Ahuka S. M.
Source
Clinical Infectious Diseases, 2022,
[Early access], [9 p.] ISSN 1058-4838
Background In October 2020, after the first wave of coronavirus disease 2019 (COVID-19), only 8290 confirmed cases were reported in Kinshasa, Democratic Republic of the Congo, but the real prevalence remains unknown. To guide public health policies, we aimed to describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibodies in the general population in Kinshasa. Methods We conducted a cross-sectional, household-based serosurvey between 22 October 2020 and 8 November 2020. Participants were interviewed at home and tested for antibodies against SARS-CoV-2 spike and nucleocapsid proteins in a Luminex-based assay. A positive serology was defined as a sample that reacted with both SARS-CoV-2 proteins (100% sensitivity, 99.7% specificity). The overall weighted, age-standardized prevalence was estimated and the infection-to-case ratio was calculated to determine the proportion of undiagnosed SARS-CoV-2 infections. Results A total of 1233 participants from 292 households were included (mean age, 32.4 years; 764 [61.2%] women). The overall weighted, age-standardized SARS-CoV-2 seroprevalence was 16.6% (95% CI: 14.0-19.5%). The estimated infection-to-case ratio was 292:1. Prevalence was higher among participants >= 40 years than among those <18 years (21.2% vs 14.9%, respectively; P < .05). It was also higher in participants who reported hospitalization than among those who did not (29.8% vs 16.0%, respectively; P < .05). However, differences were not significant in the multivariate model (P = .1). Conclusions The prevalence of SARS-CoV-2 is much higher than the number of COVID-19 cases reported. These results justify the organization of a sequential series of serosurveys by public health authorities to adapt response measures to the dynamics of the pandemic. Despite the early containment measures of the DRC government, the COVID-19 pandemic has spread in Kinshasa with an overall 16.6% SARS-CoV-2 seroprevalence after the peak of the first wave, which is much higher than the number of COVID-19 cases reported.
Plan de classement
Santé : généralités [050]
;
Entomologie médicale / Parasitologie / Virologie [052]
Description Géographique
CONGO
Localisation
Fonds IRD [F B010084271]
Identifiant IRD
fdi:010084271
